Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Breast Neoplasms 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Bortezomib 9Brentuximab Vedotin 7Filgrastim 6Vorinostat 5Doxorubicin 5tanespimycin 4Whole-Body Irradiation 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Paclitaxel 4Gemcitabine 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Carboplatin 4Biopsy 4sargramostim 3romidepsin 3fludarabine 3Topotecan 3Rifampin 3Prednisone 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Leucovorin 3Lenalidomide 3Irinotecan 3Fluorouracil 3Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large-Cell, Anaplastic × parsaclisib × Clear all
NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
5 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡